Compare Medpace Holdings Inc (MEDP) vs Select Medical Holdings Corporation (SEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Select Medical Holdings Corporation — how do they compare? Medpace Holdings Inc trades at $534.38 (market cap $15.08B), while Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B). The key difference: Medpace Holdings Inc is far larger — about 7.4× Select Medical Holdings Corporation's market cap, and Select Medical Holdings Corporation pays a 1.51% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | SEM | |
|---|---|---|
Market Cap | $15.08B | $2.05B |
Sector | Technology | Health |
52-Week High | $620.59 | $16.66 |
52-Week Low | $308.88 | $11.77 |
Enterprise Value | $14.55B | $5.01B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Select Medical Holdings Corporation (SEM) trades at $16.51, unchanged on the day, following its recent acquisition completion by a consortium led by Robert A. Ortenzio and Martin F. at $16.50 per share. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported 2025 revenue of $5.45 billion with a net income margin of 2.42%, while valuation ratios like a P/E of 15.43 and P/S of 0.36 appear reasonable. Recent earnings show two misses in the last three quarters against expectations.
The investment outlook is dominated by the completed acquisition, effectively capping upside near the $16.50 deal price. Risks include ongoing shareholder litigation alleging fiduciary breaches by the board regarding the buyout fairness. Analyst sentiment is neutral with a Hold-heavy consensus, while the stock's future price action will largely hinge on legal outcomes surrounding the acquisition terms rather than operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Select Medical Holdings Corporation
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →
